Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocular Safety of Fluticasone Furoate in PAR
NCT00682643Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2008
- Primary completion
- Feb 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in perennial allergic rhinitis (PAR) comparing Fluticasone Furoate with Placebo (2 arms). Primary endpoints: Cumulative Proportion of Participants With a Posterior Subcapsular Opacity Event at 104 weeks and Cumulative Proportion of Participants With an Intraocular Pressure Event at 104 weeks. Started Jun 2008; status: completed.
02
Drugs
fluticasone
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00682643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00682643.